We are improving the lives of people suffering from mental illness and substance use disorders

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

JANUARY 26, 2023
Orexo Interim Report Q4 2022, incl. Full Year Report

JANUARY 25, 2023
New blog post - "Charlie’s overdose: why we need to tell young people about fake pills"

JANUARY 18, 2023
Invitation to presentation of Orexo's Interim Report Q4 2022 incl. Full Year Report

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Small Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).

MODIA® - our digital therapy for opioid use disorder

  • to be used along with pharmaceuticals
  • 180 days treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. more than 430 patients

Orexo Social

31 January 2023

Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Opera… https://t.co/8nhwCYB7hL

26 January 2023

O4 Report - Important steps forward in a challenging environment. Read the PR here: https://t.co/waSrsib4HC To just… https://t.co/coLzf86ELS

25 January 2023

Our Q4 Report will be published tomorrow at 8 am CET. In the afternoon at 2 pm investors, analysts & media are much… https://t.co/S1J4xbAa4o

Financial Snapshot

Group net revenues

624.3  MSEK

LTM1

Group EBITDA

-115.2 MSEK

LTM1

US Pharma segment EBIT

308.4 MSEK

LTM1

Cash position

359.1 MSEK

Q4 2022

1 Last Twelve Months, Q122-Q422, for more information about financial development Link